ConvaTec is a leading global manufacturer of widely popular infusion sets offering a variety of patient choice Beta Bionics is developer of the iLet Bionic Pancreas System and is committed to device interoperability and patient choice ConvaTec will manufacture infusions sets for delivery of both insulin and glucagon via the iLet Bionic Pancreas System Boston, […]
The round was co-led by new investors Perceptive Advisors and Soleus Capital New investor Farallon Capital also participated in the round, as did previous Series B investors RTW Investments, ArrowMark Partners and funds managed by Eventide Asset Management Funds will support final product development, regulatory submission and commercial launch of the iLet TM Bionic Pancreas […]
First home-use trial of the iLet Bionic Pancreas System using pre-filled cartridges of dasiglucagon compatible with iLet has been successfully completed The preliminary study results reveal superior blood glucose control during the study period that used the bihormonal configuration of the iLet with dasiglucagon compared to the period that used the insulin-only configuration iLet therapy […]
First home-use trial of the bihormonal iLet Bionic Pancreas System with dasiglucagon in a pre-filled, commercial-ready, pump cartridge has been initiated by a clinical team at Massachusetts General Hospital The iLet Bionic Pancreas System is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes Dasiglucagon is a potential first-in-class stable […]
New investors include ArrowMark, LifeSci Venture Partners, and strategic partner, Dexcom RTW made an additional Series B investment Strategic partner, Zealand Pharma completed $5 million Series B investment BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) — Beta Bionics, Inc. – a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the world’s first autonomous […]
Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant provides up to $2 million in funding over the next 24 months under the Fast-Track mechanism (pending demonstration of successful achievement of Phase I milestones) Research activities directed toward the Beta Bionics insulin-only and bihormonal bionic pancreas technology. Boston, MA – […]
The round was led by Eventide Asset Management Other institutional investors in Series B include RTW Investments Corporate strategic partner and Series A investor, Novo Nordisk, has also participated in Series B Corporate strategic partner, Zealand Pharm, previously committed $5m to Series B in December 2017 Boston, MA – September 17, 2018 – Beta Bionics, Inc. […]
The Beta Bionics iLet Bionic Pancreas System is now approved for clinical trials in adults with type 1 diabetes (T1D) using two highly accurate continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM iLet compatibility with both CGM systems demonstrates unique commitment by Beta Bionics to patient choice, interoperability, and the […]
First trial to test Fiasp® – Novo Nordisk’s latest formulation of fast-acting insulin aspart – using autonomous insulin delivery The bionic pancreas will also be tested with the conventional formulations of insulin aspart and insulin lispro in both adults and children with type 1 diabetes who use either an insulin pump or multiple daily injection […]
Zealand Pharma makes an initial USD 1.5 million equity investment in the Series B offering of Beta Bionics, Inc., developer of the iLet, a fully integrated dual-hormone pump (bionic pancreas) for autonomous diabetes care Subsequent equity investments of up to USD 3.5 million are linked to clinical development progress of dasiglucagon in the iLet Zealand’s […]
We are committed to balancing purpose with profit and giving back to society as we fulfill our public benefit mission.
Safety Information – The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at www.betabionics.com/resouces/user-guides, or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to www.betabionics.com/resources/safety. DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.
Medical Disclaimer – This website is for information only and is not a substitute for medical advice and/or services from a healthcare provider. All personal health care decisions and treatment should be discussed with a healthcare provider who is familiar with your individual needs.
Copyright © 2024 Beta Bionics | Privacy Policy | Safety | Terms of Use | Cookies | Patents | Code of Conduct